Human Milk Concentrating Device to Optimize Mother's Own Milk (NEOMOM)
Noninferiority Evaluation of Human Milk Concentrating Device to Optimize Mother's Own Milk
This study is a randomized, non-inferiority clinical trial evaluating a human milk concentration (HMC) device in preterm infants. The trial compares outcomes in infants fed mother's own milk (MOM) concentrated using the HMC device to those receiving standard of care feeding with MOM supplemented with cow's milk-based fortifiers or formula.
The primary objective is to determine whether infants receiving HMC-concentrated MOM achieve growth and mineral status that are non-inferior to standard of care, as measured by growth velocity through 28 days of life or hospital discharge and serum phosphate levels at 14 days of life.
Secondary objectives include assessment of clinical safety through evaluation of feeding tolerance, weight gain, and serum chemistries during the study period. The study will also evaluate the cost and resource utilization associated with feeding strategies by comparing preparation time, supply costs, total feeding costs, and overall neonatal intensive care unit (NICU) cost of care, including length of stay.
연구 개요
상태
상세 설명
Preterm infants often require nutritional supplementation to support adequate growth and bone mineralization during hospitalization. Current standard of care commonly involves the addition of cow's milk-based fortifiers or formula to mother's own milk (MOM), which may introduce variability in feeding practices, added cost, and exposure to non-human milk components.
This study evaluates a human milk concentration (HMC) device designed to increase the nutrient density of MOM through passive water removal using forward osmosis. The device enables concentration of MOM without the addition of bovine-derived products and is intended to integrate into existing neonatal intensive care unit (NICU) feeding workflows.
The study is a randomized, controlled, non-inferiority trial conducted in preterm infants receiving enteral nutrition in the NICU. Participants are assigned to receive either MOM concentrated using the HMC device or standard of care feeding consisting of MOM with supplementation per institutional practice. Feeding preparation and administration are performed according to site-specific protocols.
Clinical assessments are conducted throughout the study period to evaluate infant growth, nutritional status, and overall clinical stability. Safety monitoring includes routine clinical evaluations and laboratory assessments consistent with standard NICU care. In addition, data are collected to assess resource utilization and costs associated with feeding preparation and overall care during hospitalization.
The goal of this study is to generate evidence on whether concentrating MOM using the HMC device can provide a clinically comparable alternative to standard supplementation practices while potentially reducing reliance on bovine-derived products and impacting healthcare resource utilization.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Elizabeth Nelson, PhD
- 전화번호: 2679818066
- 이메일: enelson@mmib.health
연구 장소
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06511
- Yale University
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Birth at 32 0/7 to 34 5/7 weeks' gestational age, with a birthweight above 1500 grams and receiving MOM
- Enteral feeding must be initiated within 48 hours post-birth and the infant must meet the NICU's clinical guidelines for feed fortification/supplementation.
- Multiples are eligible and will be randomized to the same group since the intervention affects MOM preparation.
Exclusion Criteria:
- Major congenital anomalies
- Contraindication to receiving MOM
- Feeds not started by 2 days post-birth
- Fortification/supplementation not ordered by 5 days post-birth,
- Inadequate MOM for concentration/fortification within 5 days post-birth
- Expected transfer to another hospital
- Expected hospital discharge within 14 days post-birth
- Enrollment in another intervention study with an intervention that could affect infant growth or mineral status
- Infant with contraindications for use of the HMC device
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: HMC-Concentrated MOM
Preterm infants receive enteral feedings of mother's own milk that has been concentrated using the HMC device to increase nutrient density without the addition of bovine-derived fortifiers.
|
A sterile, single-use human milk concentration device used to passively remove water from mother's own milk prior to feeding, increasing nutrient density without the addition of bovine-derived fortifier.
|
|
활성 비교기: Standard Fortified Feeding (MOM + Fortifier/Formula)
Preterm infants receive enteral feedings of mother's own milk supplemented with cow's milk-based fortifier or formula according to institutional standard of care.
|
Mother's own milk supplemented with cow's milk-based human milk fortifier and/or formula according to institutional standard of care.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Growth Velocity
기간: Birth to 28 days of life or hospital discharge, whichever occurs first
|
Average daily weight gain normalized to body weight in preterm infants receiving assigned feeding strategy.
|
Birth to 28 days of life or hospital discharge, whichever occurs first
|
|
Serum Phosphate Level
기간: 14 days of life
|
Serum phosphate concentration as a marker of mineral status in preterm infants receiving assigned feeding strategy.
|
14 days of life
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Feeding Tolerance
기간: Up to 28 days of life or hospital discharge
|
Clinical assessment of feeding tolerance based on physical examination and incidence of feeding intolerance events during the study period.
|
Up to 28 days of life or hospital discharge
|
|
Weight Gain Monitoring
기간: Daily through 28 days of life or discharge
|
Serial assessment of infant weight to evaluate adequacy of growth during the study period.
|
Daily through 28 days of life or discharge
|
|
Feeding Preparation Cost
기간: Up to 28 days of life or discharge
|
Cost associated with preparation of feedings, including staff time and materials required for each feeding strategy.
|
Up to 28 days of life or discharge
|
|
Total Feeding Cost
기간: First 28 days of life or until discharge
|
Total cost of feeding over the study period, including milk, fortifier, formula, and preparation time.
|
First 28 days of life or until discharge
|
|
Length of Stay
기간: From birth to hospital discharge (up to 10 weeks)
|
Duration of hospitalization in the NICU.
|
From birth to hospital discharge (up to 10 weeks)
|
|
Total NICU cost of care
기간: From birth to hospital discharge (up to 10 weeks)
|
Total hospital costs incurred during NICU stay, including all resources utilized.
|
From birth to hospital discharge (up to 10 weeks)
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Sarah Taylor, MD, Yale University
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- MMIB-NEOMOM-2000042290
- R44HD110306 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD Description:
De-identified individual participant data underlying the results reported in this study, including baseline characteristics and outcome measures, may be shared.
Access Criteria:
Data will be made available to qualified researchers upon reasonable request, subject to review and approval by the study sponsor. Access will require a data use agreement and must comply with applicable privacy and regulatory requirements.
IPD 공유 기간
IPD 공유 액세스 기준
IPD 공유 지원 정보 유형
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Human Milk Concentration Device에 대한 임상 시험
-
Instituto de Investigacion Sanitaria La FeHospital Universitario La Fe모병